April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Additives Can Lessen Acute Corneal Epithelial Disorder Induced by Xalatan®
Author Affiliations & Notes
  • M. Kusano
    Ophthalmology,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • M. Uematsu
    Ophthalmology,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • K. Shimoda
    Hospital Pharmacy,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • M. Teshima
    Hospital Pharmacy,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • T. Kumagami
    Ophthalmology,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • H. Sasaki
    Hospital Pharmacy,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • T. Kitaoka
    Ophthalmology,
    Nagasaki Univ School of Medicine, Nagasaki, Japan
  • Footnotes
    Commercial Relationships  M. Kusano, None; M. Uematsu, None; K. Shimoda, None; M. Teshima, None; T. Kumagami, None; H. Sasaki, None; T. Kitaoka, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4612. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Kusano, M. Uematsu, K. Shimoda, M. Teshima, T. Kumagami, H. Sasaki, T. Kitaoka; Additives Can Lessen Acute Corneal Epithelial Disorder Induced by Xalatan®. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4612.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate acute corneal epithelial disorders induced by the antiglaucomatous prostaglandin analogues Xalatan®, containing 0.02% benzalkonium chloride (BAC); Travatan®, containing 0.015% BAC; Travatanz®, without BAC; and, Travatan® additives. A second aim was to determine whether additives included in ophthalmic drugs can lessen the extent of acute corneal epithelial disorders induced by Xalatan®.

Methods: : The corneal transepithelial electric resistance (TER) of live rabbits was measured before and after 60 seconds of exposure to Xalatan®, Travatan®, Travatanz®, and Travatan® additives. Cultured normal rabbit corneal epithelial (NRCE) cells were also exposed to the same drugs for 60 seconds and cell viability was evaluated using a WST-1 assay. Finally, the Travatan® additive, 1% polyoxyethylene hydrogenated castor oil (HCO), was mixed with 0.02% BAC and Xalatan®, and changes in TER, cell viability, and scanning electron microscopy (SEM) were examined.

Results: : Xalatan® significantly lowered TER (P < 0.0001) and NRCE viability (P < 0.0001), whereas Travatan® and Travatanz® did not significantly differ compared with the control. However, the mixture of 1% HCO, 0.02% BAC and Xalatan® did not significantly alter TER and cell viability compared with the control, and SEM did not detect any damage to the corneal epithelial superficial cells.

Conclusions: : The inclusion of 1% HCO can lessen the extent of acute corneal epithelial disorder caused by 0.02% BAC and Xalatan®.

Keywords: cornea: epithelium • cornea: basic science • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×